Bone Abstracts

The aim of the study is to compare the performance of FRAX vs TBS adjusted FRAX using Leslie B et al.1 method to better identify women at high fracture risk. The OsteoLaus cohort (1500 women 50–80 years living in Lausanne, CH) started in 2010. CRF for OP, FRAX, spine and hip BMD, VFA by DXA and TBS were recorded. Sensitivity and specificity in regard to vertebral fracture grade 2 and 3 has been calculated. Net reclassification improvement (NRI) had als...

Introduction: Mortality after hip fracture is increased. However, only a few studies have explored for predictors beyond gender and age. Thus our aim was to study risk factors associated with increased mortality in hip fracture patients.Methods: Hip fracture patients (>50 years) admitted to a county hospital in 2004–2005 were consecutively invited for assessment at the hospital osteoporosis centre. A broad spectre of data was collected. Standard...

Introduction: Since the identification of the fact that osteoporosis represents not quite rare disease in men, its preconditions-diseases increasing the likelihood of osteoporosis in men has been intensively studied. As a result, a new direction ‘male osteoporosis’ has been established in medicine, although, there is not sufficient information on how the basic medications are selected for men; whether certain drugs have priority effect for the treatment of osteoporos...

Introduction: Persistence is defined as the period between the start and the interruption of a pharmacological treatment. In osteoporotic patients, persistence to therapy is poor, resulting in reduced benefits and increased risk of fracture.The aim of this study is to analyze persistence with drug therapy in osteoporotic patients in the Campania region.Material and methods: We conducted a retrospective population-based cohort study to examine prescriptio...

Introduction: To analyze clinical assessment and efficacy of once-yearly i.v. zoledronic acid for osteoporosis.Materials and methods: The subjects were 322 osteoporotic patients who received more than single infusion of zoledronic acid in our hospital from October 2008 to March 2011. On clinical assessment, the adherence was evaluated by measuring the rate of reinfusion. Adverse events were recorded for safety assessment. For efficacy assessment, the bon...

Introduction: We aimed to study efficacy of zoledronic acid (Zol) in the treatment of postmenopausal osteoporosis within 3 years.Methods: Clinical, bone mineral density (BMD) by DEXA (L1–L4, femoral Neck) (baseline, 12, 24, and 36 months); biochemical; immunoenzyme assay of bone turnover markers (BTM) – osteocalcin (OK) β-C-terminal telopeptides of type 1 collagen (CTX) (baseline, 1, 3, 6, 9, and 12 after one, two, three infusions).<p ...

Zoledronic acid (AZ), is considered first-line treatment for Paget’s disease (PD) of bone. The most common adverse event is flu-like syndrome, described between 10 and 50% of patients. Nowadays, there is not known exactly the molecular basis of this syndrome yet. Statins play an important role in the mevalonate pathway, blocking the production of proinflammatory cytokines secreted by T cells γ/δ.Objectives: Characterization and in...

ExFOS is a multicenter, prospective, observational study to evaluate fracture outcomes, back pain, compliance and health-related quality of life in female and male patients with osteoporosis treated with teriparatide [rhPTH(1–34)] (Forsteo)for 18 to 24 months. Post-treatment follow-up will last for at least 18 months. Patients were enrolled in Croatia, Denmark, France, Greece, Italy, Norway, Slovenia, and Sweden. The study design was non-interventional and all consenting ...

Zoledronic acid has been shown to reduce the risk of fractures and improve bone mineral density (BMD) in osteoporosis vs placebo. This study compared changes in BMD in patients with osteoporosis treated with zoledronic acid vs alendronate. BMD at the lumbar spine and total hip pre- and post-bisphosphonate were recorded for 65 patients with osteoporosis (T score ≤−2.5) from retrospective analysis of DEXA scans. 35 patients received annual 5 mg IV zoledronic...

Odanacatib (ODN) is an orally-active cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN 50mg once weekly on BMD, bone turnover markers and safety in patients previously treated with alendronate (ALN).This was a randomized, double-blind, placebo-controlled, 24-month study. The primary endpoint was % change from baseline at month 24 of femoral neck (FN) BMD. Postmenopausal women (...